Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies

NCT05336409 is registered in ClinicalTrials.gov with Century Therapeutics, Inc. as lead sponsor.

NCT NCT05336409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05336409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ELiPSE-1 Study: A Phase 1, Multicenter, Open-Label Study of CNTY-101 in Subjects With Relapsed or Refractory CD19-Positive B-Cell Malignancies
Lead sponsor
Century Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
January 24, 2023
Completion date
July 1, 2025
Enrollment
28 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

aggressive non-hodgkin lymphoma, indolent non-hodgkin lymphoma, r/r cd19-positive b-cell malignancies